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Abstract 
Nogo-A, a major myelin inhibitory protein, inhibits axon growth and synaptic 
function in the central nervous system. Glaucoma is a progressive neuropathy as a 
result of retinal ganglion cell (RGC) death. Synaptic degeneration is thought to be an 
early pathology of neurodegeneration in glaucoma and precedes RGC loss. Here 
experimental ocular hypertension model was induced in adult rats with laser 
coagulation of the episcleral and limbal veins. The expression of Nogo-A, 
myelin-associated glycoprotein (MAG) and oligodendrocyte myelin glycoprotein 
(OMgp) in the retina was investigated using immunohistochemistry and Western 
blotting. We found that Nogo-A was expressed in the RGCs and upregulated after the 
induction of ocular hypertension. OMgp was only expressed in the inner plexiform 
layer. There was no MAG expression in the retina. Our data provided, for the first 
time, the expression patterns of three myelin protein in the adult retina and suggested 
an important role of Nogo-A in the RGC death and synaptic degeneration in 
glaucoma. 
 
Key words: Ocular hypertension, Nogo-A, Myelin-associated glycoprotein, 
Oligodendrocyte myelin glycoprotein, Retina 
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Introduction 
Glaucoma is a neurodegenerative disease characterized by the degeneration of 
retinal ganglion cells (RGCs) and their axons. Increasing evidence also supports the 
presence of compartmentalized degeneration in the synapses [1-3] and may underlie 
visual functional deficits in glaucoma. We previously identified that there is synaptic 
degeneration for RGCs in an ocular hypertension model of glaucoma and it may 
precede the RGC death [4]. These findings suggest that the synapse destruction could 
contribute significantly to the progressive nature of vision loss in glaucoma. Devising 
ways to induce such a reversal could represent an effective potential approach to 
neuroprotection.  
The failure of axonal regeneration within the damaged adult central nervous 
system (CNS) has been ascribed in part to the presence of Nogo-A[5] 
myelin-associated glycoprotein (MAG) [6] and oligodendrocyte myelin glycoprotein 
(OMgp) [7,8]. All three bind the Nogo66 receptor (NgR1) [9] and the paired 
immunoglobulin-like receptor B (PirB) [10] to mediate their inhibitory influence. 
Although Nogo-A is thought to be the primary source of the Nogo related limitation 
of neuronal outgrowth after injury [5,11], much data demonstrates that Nogo-A is 
expressed by many populations of neurons in the CNS, and is not limited to 
oligodendrocytes [12-15]. Nogo-A expression was increased in the cortical neurons 
[16] and anti-Nogo-A antibody improves functional recovery in adult rats after stroke 
[17]. Nogo protein was detected in the retina of mouse embryos [18] and in the 
neonatal rat [19]. Neuronal Nogo-A may be involved in normal cell-functioning 
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separate from the post injury outgrowth-inhibitory role observed for oligodendroglial 
Nogo-A[15]. Nogo-A plays a role in the maintenance of inhibitory synapses in 
cerebellar Purkinje cells [20] and motor neuron in amyotrophic lateral sclerosis (ALS) 
[21]. Unlike Nogo-A, MAG is not expressed in neurons but in glia of CNS and 
peripheral nerves [22]. OMgp was first identified as a myelin protein but has 
subsequently been found to be expressed on some neurons in the CNS [23]. However, 
there were no reports for Nogo-A, MAG and OMgp in the retina of adult animals and 
in glaucoma. In this study, we provide evidence that Nogo-A, but not OMgp and 
MAG protein increased in the retina in an ocular hypertension model in rats. High 
levels of Nogo-A may be a possible mechanism of the RGC death and synapse 
degeneration in the glaucoma.  
 
Experimental Procedure 
Animals 
Animal experiments were approved by the University of Hong Kong Faculty 
Committee on the Use of Live Animals in Teaching and Research. Twenty two adult 
female Sprague-Dawley (SD) rats (starting weight, 250-280 g) were used for the study. 
The animals were anesthetized with intraperitoneal injection of ketamine (80 mg/kg) 
and xylazine (8 mg/kg) during the experiments and were euthanized at the end of the 
experiment with an overdose of pentobarbital sodium (150 mg/kg). Alcaine 0.5% 
(Alcon-Couvreur, Belgium) was applied to the eyes before all operations and 
antiseptic eye drops (Tobres [Tobramycin 0.3%], Alcon-Couvreur, Belgium) were 
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5 
used to prevent infection after the surgery. Rimadyl (0.025mg/ml) in drinking water 
was used as analgesics for 7 days after the surgeries. 
 
Induction of experimental ocular hypertension 
Argon laser (Ultima 2000SE Argon Laser, Coherent, Palo Alto, CA) was used to 
coagulate the limbal and episcleral veins in the right eye of the rats. This technique 
was adopted from the method by WoldeMussie et al [24] and has been adopted in our 
laboratory for the retina degeneration and therapeutic effects on retina functions 
[4,25-27]. About 90 spots were applied on the three episcleral veins and 70 spots on 
the limbal vein (270° around the limbus, except on the nasal side) with the following 
settings: power of 1000 mW; spot size of 50 µm in diameter; and duration of 0.1s. A 
secondary laser surgery was performed to coagulate the reconnected blood vessel 
seven days later. The intraocular pressure (IOP) of the eyes were measured using a 
Tonopen XL Tonometer. Fluorogold (FG) labeling of RGCs was performed 7 days 
before sacrifice. Both superior colliculi (SC) were exposed after removing a small 
piece of skull and cortex, and a piece of Gelfoam (Pharmacia & Upjohn, Kalamozoo, 
MI, USA) soaked with FG (6% in distilled H2O, Fluorochrome, Denver, CO, USA) 
was placed on the surface of SC. Rats were euthanized with an overdose of anesthesia 
2 weeks after the first laser exposure for RGC labeling.  
 
Immunohistochemistry of Nogo-A, MAG, OMgp 
The animals were euthanized with an overdose of anesthesia at 0, 2 and 4 weeks after 
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6 
the first laser coagulation. The eyes were enucleated following transcardial perfusion 
with 0.9% saline and were fixed in 4% PFA for 1 h. After removing the corneas and 
lens, the eye cups were fixed further in PFA for 4 h and then transferred to 30% 
sucrose solution at 4ºC for 16 h. Ten-micron-thick frozen retinal sections were washed 
in 0.01M phosphate buffered saline (PBS) and were incubated in 0.5% Triton/PBS for 
10 min. After being blocked with 10% normal goat serum for 1 h, the sections were 
incubated with rabbit anti-Nogo-A (1: 100, CalBioChem, CA, USA), mouse 
anti-MAG (1:100, Chemicon, Hofheim, Germany) and mouse anti-OMgp (1:100, 
Chemicon, Hofheim, Germany) antibodies at 4ºC for 16 h. Sections then were washed 
with PBS three times and incubated with Alexa Fluor® 488 goat anti-rabbit second 
antibody (1:400, Molecular probes, Oregon, USA) at room temperature for 2 h. 
Negative control was performed on the retina sections at 2 weeks after the induction 
of ocular hypertension with only incubation of Alexa Fluor® 488 goat anti-rabbit 
second antibody. The positive control for Nogo-A was performed by staining Nogo-A 
in the optic nerve from normal retina in the adult rat. The sections were analyzed 
under Olympus IX71 fluorescent microscope with DP2-BSW software (Olympus, 
Japan). Six animals were used in each group. 
 
Western Blotting for Nogo-A 
To measure Nogo-A in the retina, the animals were euthanized at 0, 5 days, 2 and 4 
weeks after laser coagulation. The retinas were dissected and homogenized in lysis 
buffer (10 mM Tris pH7.4, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA) supplemented 
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7 
with 10% protease inhibitor cocktail and 1% phosphatase inhibitor cocktails from 
Sigma. Following centrifugation at 13,000 rpm for 30 min to remove cell debris, the 
protein concentration of the supernatant was measured using a Bio-Rad DC protein 
Assay Kit (Bio-Rad Laboratories, CA, USA). A 40-80 µg aliquot of proteins from 
each sample was subjected to 6% (for Nogo-A) or 10% (for β-actin) 
SDS-polyacrylamide gel electrophoresis and transferred onto PVDF membrane. The 
membranes were blocked with Odyssey blocking buffer (LI-COR, Inc., lincoln，NE, 
USA) for 1 h in room temperature. Incubation with goat anti-Nogo-A (1:100, Santa 
Cruz Biotechnology, CA, USA) antibody was performed for 16 h at 4ºC. After 
washing, the membranes were incubated with IRDye 800CW goat anti-mouse 
secondary antibody (1:2000, LI-COR, Inc., lincoln，NE, USA) in Odyssey blocking 
buffer for 1 h at room temperature. Protein loading was controlled using a mouse 
antibody against anti-actin (1:2000, Chemicon, Hofheim, Germany) and finally 
incubated with IRDye 800 goat anti-mouse secondary antibody (1:2000, LI-COR, Inc., 
lincoln，NE, USA). The membranes were scanned and analyzed using Odyssey 
Infrared Imaging System (LI-COR, Inc., lincoln，NE, USA). All experiments for 
Western blotting were performed with 5 animals in each group and repeated 3 times. 
 
Statistics 
All data are expressed as Mean ± SEM. Statistical analysis was evaluated by one-way 
analysis of variance (ANOVA) followed by post-hoc tests (Student-Neuman-Keuls) 
for comparisons between groups. The mean difference is significant at 0.05 level. 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
8 
Data were analyzed statistically with the software SPSS 12.0 (SPSS Inc., Chicago, 
Illinois, USA). 
Results 
Nogo-A expression in the normal rat retina 
The expression of Nogo-A in the retina was evaluated using immunohistochemisty. 
Negative control only with second antibody showed no positive staining in the retina 
at 2 weeks after ocular hypertension (Fig. 1a-b). Nogo-A was reported to express in 
the oligodendrocytes. Here we found strong immunostaining for Nogo-A in the optic 
nerve with myelin sheath of normal adult rat (Fig. 1c). Nogo-A positive staining was 
visible mainly in the ganglion cell layer (GCL) and the nerve fiber layer (NFL) in the 
normal retina (Fig.1d-f). Less immunoreactive staining was observed in the other 
layers. Next we examined whether RGCs expressed Nogo-A. The retrograde FG 
staining for RGCs was mainly distributed in the cytoplasm. Here we identified that 
Nogo-A was expressed in the FG-labeled RGCs (Fig. 1j-l). Some Nogo-A positive 
cells in GCL were not FG-labeled RGCs. Since amacrine cells are the other major 
types of cells in the GCL, amacrine cells in GCL may also express Nogo-A protein. 
 
Increased Nogo-A expression after the induction of ocular hypertension 
We induced an ocular hypertension model in adult rats. Similar to our previous reports, 
the IOPs were found to be 23.45 ± 0.79 mmHg and 24.32 ± 0.82, respectively, in the 
glaucomatous eyes at 2 weeks and 4 weeks after laser treatments, and 13.24 ± 0.46 
mmHg in the normal eyes (P < 0.01). In the glaucomatous retina, high levels of 
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9 
Nogo-A was detected in the RGCs. Strong Nogo-A immunostaining was found in the 
inner plexiform layer (IPL) and outer nuclear layer (ONL) (Fig. 1g-i, m-o). This was 
confirmed using Western blotting. Nogo-A expression increased at 5 days after IOP 
elevation and there was up to 3 fold increase of the Nogo-A protein at 2 and 4 weeks 
(Fig. 2, P < 0.05 compared to normal retina). No difference was found for the Nogo-A 
levels between 2 weeks and 4 weeks (P > 0.05). 
 
MAG and OMgp expression after the induction of ocular hypertension 
We further examined the expression of the other two myelin proteins in the retina. 
MAG protein was not detected in the retinas of normal and glaucomatous animals 
(Fig. 3a). FG-labeled RGCs did not express MAG protein. No MAG expression was 
found in the beginning portion of the optic nerve without myelin sheath. MAG was 
only observed in the part of the optic nerve with myelin sheath (Fig. 3a). There was a 
clear ridge for MAG expression in the longitudinal section of the optic nerve with the 
optic disk. We further identified that there was low level of OMgp in the IPL in the 
normal retina using immunohistochemistry (Fig. 3b). There was no OMgp 
immunostaining in the FG-labeled RGCs (Fig. 3b). No difference was found for 
OMgp protein in the retina before and after the induction of ocular hypertension (Fig. 
3b). 
 
Discussion 
Here we demonstrated that Nogo-A was expressed in the normal retina and was 
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increased in a rat glaucoma model. We further identified that RGCs expressed 
Nogo-A. There was no MAG expression in the retina and OMgp was only expressed 
in the IPL. It is the first report about the expression of three myelin proteins in the 
adult retina and in a rat model of ocular hypertension. The data suggest an important 
role of Nogo-A in the normal retina and after ocular hypertension. 
Glaucoma is a common eye disease that can cause irreversible loss of vision if 
left undiagnosed and untreated. Compartmentalized degeneration in the synapses may 
underlie visual functional deficits in glaucoma [1-3]. Early changes in RGC dendrites 
have critical consequences on synaptic efficacy and may underlie functional deficits 
in glaucoma [28-30]. The loss of visual sensitivity in the early stages of 
experimentally induced glaucoma could be attributed to a loss of connectivity 
secondary to synaptic degeneration [1]. We previously identified that synaptic 
degeneration for RGCs may precede the RGC death in an ocular hypertension model 
[4]. However, it is unclear for the mechanisms for the synaptic degeneration in 
glaucoma. The model used in this study mimics the slow, progressive neuropathy 
produced by elevated IOP in humans by partially obstructing aqueous humor outflow, 
similar to elevated episcleral venous pressure glaucoma. However, there are still some 
differences between this animal model and human glaucoma disease. Human chronic 
glaucoma is a progressive optic neuropathy characterized by slow visual field loss 
with a long-term-even several decades long-course, whereas there was significant 
RGC loss in several weeks in this rat ocular hypertension mode. Even so, the finding 
of increased Nogo-A expression partly indicates that the Nogo-A may play some role 
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11 
for vision loss in the human glaucoma. 
Previous opinions for myelin proteins are that they are limited to 
oligodendrocytes. However, much current data demonstrate that Nogo-A is expressed 
in many populations of neurons in the CNS. Our findings of the expression of Nogo-A 
in the RGCs in rats is consistent with previous reports that Nogo-A is expressed in the 
embryo or neonatal animals [18,19]. Besides the inhibition of axonal regeneration or 
neurite outgrowth, Nogo-A plays an important role in synapse maintenance and neural 
survival. Nogo-A genetic deletion resulted in prolonged cell survival in addition to 
axonal regeneration in mice with amyotrophic lateral sclerosis [31]. Nogo-A could 
signal transsynaptically as observed e.g. for Ephrins to regulate synapse maintenance 
[32-34]. The reduction of Nogo-A expression in the cell-Deep Cerebellar Nuclei 
correlates with synapse maturation [20]. The upregulation of Nogo-A in our model is 
consistent with previous reports about the increased expression of Nogo-A in 
Alzheimer disease [35], in muscles and spinal cord motoneurons of amyotrophic 
lateral sclerosis [36]. The increased expression of Nogo-A may be a primary factor 
leading to the synaptic function deficits and further RGC death. It is interesting that 
we found increased Nogo-A expression at 5 days after IOP elevation. We previously 
identified that there was significant synaptic degeneration but no RGC loss at 5 days 
in this ocular hypertension model [4]. The early upregulation of Nogo-A provide 
further evidence that Nogo-A may firstly affect synaptic function and then lead to the 
secondary RGC death. Furthermore, our data showed that there was no difference for 
Nogo-A levels at 2 weeks and 4 weeks after IOP elevation. It suggests that Nogo-A 
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12 
protein reaches a saturation under the balance of production and cleaning. In this 
model, RGC loss stabilizes after 4 weeks [37]. The stability of Nogo-A accumulation 
after 2 weeks may has some relationship with the stabilization of RGC loss. 
Our study indicates that some amacrine cells may also express Nogo-A. 
Amacrine cells in the vertebrate retina are interneurons that interact at the second 
synaptic level in the pathways consisting of the photoreceptor-bipolar-ganglion cell 
chain. They are synaptically active and serve to integrate, modulate and interpose a 
temporal domain to the visual message presented to the ganglion cell. The expression 
of Nogo-A in amacrine cells may be one of stations of Nogo-A to affect the synaptic 
function. 
LINGO-1 (LRR and Ig domain-containing, Nogo Receptor-interacting protein-1) 
[38] was a member of NgR1 signaling complexes that prevent axonal regeneration in 
the presence of three myelin inhibitors. Because NgR1 is a GPI anchored protein, 
LINGO-1 and the other co-receptors, p75/TROY transduce the myelin inhibitory 
signal into the cells. We found that blocking LINGO-1 function promotes survival of 
damaged RGCs in a chronic adult rat ocular hypertension model [25]. The 
upregulation expression of Nogo-A after IOP elevation provides a possibility that 
LINGO-1 antagonists disturb the function of Nogo-A and NgR1, and then exert the 
neuroprotection. It may be one of the mechanisms how LINGO-1 antagonist promotes 
RGC survival. 
In this study, we found that Nogo-A, but not OMgp and MAG protein increased 
in the retina after ocular hypertension. It may provide a possible mechanism 
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underlying the synapse degeneration and RGC death in glaucoma. 
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Figure Legends 
 
Figure 1  Immunohistochemistry of Nogo-A in the normal and ocular 
hypertensive retina. (a) Negative control for Nogo-A expression in the retina at 2 
weeks after ocular hypertension. (b) The same visual field showed fluorogold labeled 
retinal ganglion cells in (a). (c) Nogo-A expression in the optic nerve in adult rat as 
positive control. Nogo-A was expressed in the ganglion cell layer in the normal retina 
(d, j). Retinal ganglion cells (RGCs) expressed Nogo-A (white arrow heads) (j-l). 
Some Nogo-A positive cells in the GCL were not FG-labeled RGCs (white arrows). 
Strong Nogo-A expression was found in RGCs (white arrow heads and red arrows), 
especially for RGCs in the GCL, in the IPL and INL at 2 weeks after ocular 
hypertension (m-o). The pictures in the boxes in i-l and m-o were enlarged below. 
Nogo-A staining (green); FG-labeled RGCs (blue); merge of Nogo-A and FG labeling 
(orange). We regarded red as the color of FG in the picture of merge. GCL, ganglion 
cell layer; INL, inner nuclear layer; ONL, outer nuclear layer; FG, fluorogold.  
 
Figure 2 Western blot of Nogo-A in the normal and ocular hypertension retinas. 
Nogo-A expression in the normal and injured eyes with Western blotting and 
densitometric analysis of Western blot analysis (P < 0.05, compared with normal 
retina). n = 5 animals per group. 
 
Figure 3 The expression of Myelin associated glycoprotein (MAG) and 
oligodendrocyte myelin glycoprotein (OMgp) in glaucoma. (a) MAG expression. 
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(a1) Normal retina; (a2) The retina after 2 weeks of ocular hypertension. (a3) optic 
disc in the normal retina. There was no expression of MAG in the normal retinas (a1) 
and after the induction of ocular hypertension (a2). MAG was expressed in the optic 
nerve with myelin sheaths (a3, upper picture: light micropscopy picture to show the 
optic disc structure). (b) OMgp expression. (b1) Normal retina; (b2) The retina after 2 
weeks of ocular hypertension. There was moderate expression of OMgp in the NFL, 
GCL, IPL and INL in the normal retinas (b1). OMgp expression had no change at 2 
weeks after the induction of ocular hypertension (b2). MAG or OMgp staining (green); 
FG-labeled RGCs (blue); We regarded red as the color of FG in the merged picture. 
NFL: nerve fiber layer; GCL, ganglion cell layer; INL, inner nuclear layer; ONL, 
outer nuclear layer; FG, fluorogold. n = 5 animals per group. Bar = 25 µm. 
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